オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - liquid paraffin -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

herbsense pty ltd - pyridoxine hydrochloride, quantity: 100 microgram/ml; cyanocobalamin, quantity: 0.1 microgram/ml; ferrous gluconate dihydrate, quantity: 8.6 mg/ml (equivalent: iron, qty 1 mg/ml); riboflavin, quantity: 100 microgram/ml; thiamine nitrate, quantity: 100 microgram/ml; malpighia glabra, quantity: 150 microgram/ml (equivalent: malpighia glabra, qty 600 microgram/ml); ziziphus jujuba var. spinosa, quantity: 171.4 microgram/ml (equivalent: ziziphus jujuba var. spinosa, qty 3 mg/ml) - oral liquid - excipient ingredients: maltodextrin; ascorbic acid; apple; pear; potassium sorbate; glycerol; purified water; honey; sodium hydroxide; flavour - contains iron, and b group vitamins, which support general health and well-bring. contains iron which supports red blood cell production and helps prevent dietary iron deficiency. it may assist in maintaining blood health and energy levels.

南アフリカ - 英語 - South African Health Products Regulatory Authority (SAHPRA)

marshall traditional healthcare cc - liquid - see ingredients - each 10 ml liquid contains liquid paraffin 10 ml

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

lifetime pharmaceuticals - propolis, quantity: 400 mg/ml (equivalent: lead, qty 0.4 microgram/ml; equivalent: propolis resin, qty 200 mg/ml) - liquid, multipurpose - excipient ingredients: propylene glycol - antioxidant and free radical scavenging properties.propolis is a nutritional supplement helpful in supporting the immune system. may relieve the symptoms of colds & flu. when applied topically, propolis may be beneficial in bringing relief to minor skin irritations such as insect bites and stings as well as cuts & scratches.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

lacorium health australia pty ltd - undecenoic acid, quantity: 250 mg/g - liquid, multipurpose - excipient ingredients: dl-alpha-tocopheryl acetate; aloe vera; hypromellose; purified water; melaleuca oil; eucalyptus oil; isopropyl alcohol

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

lacorium health international pty ltd - undecenoic acid, quantity: 250 mg/g - liquid, multipurpose - excipient ingredients: eucalyptus oil; urea; hypromellose; aloe vera; isopropyl alcohol; melaleuca oil; purified water; dl-alpha-tocopheryl acetate; butylated hydroxytoluene

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - codeine phosphate hemihydrate, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: glycerol; propylene glycol; sucrose; purified water; potassium sorbate; hydrochloric acid; sodium hydroxide; methyl hydroxybenzoate; propyl hydroxybenzoate; ethyl hydroxybenzoate; butyl hydroxybenzoate; isobutyl hydroxybenzoate - relief of unproductive, dry and intractable coughs associated with colds and flu.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 20 mg/ml - oral liquid, suspension - excipient ingredients: hyetellose; methyl hydroxybenzoate; purified water; dispersible cellulose; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); peg-8 stearate; sorbic acid; propylene glycol; saccharin sodium; flavour - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(131i), quantity: 1201 mbq - oral liquid, solution - excipient ingredients: sodium bicarbonate; sodium thiosulfate pentahydrate; water for injections - .